VCM
ABCL icon

Voleon Capital Management’s AbCellera Biologics ABCL Stock Holding History

Voleon Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466K Sell
59,396
-63,151
-52% -$309K 0.01% 600
2026
Q1 		$428K Sell
122,547
-142,778
-54% -$514K 0.01% 602
2025
Q4 		$907K Buy
265,325
+254,125
+2,269% +$1.13M 0.02% 460
2025
Q3 		$56.3K Buy
+11,200
New +$49.4K ﹤0.01% 869

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Voleon Capital Management's ABCL Position: Q2 2026 in Review

Voleon Capital Management reduced its AbCellera Biologics (ABCL) stake by 52% in Q2 2026, selling an estimated $309K and leaving 59,396 shares worth $466K. The position accounts for 0.01% of the portfolio, ranked #600.

Voleon Capital Management first reported a position in ABCL in Q3 2025 and has held it in 4 quarters since. The position peaked at $907K in Q4 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Voleon Capital Management held 59,396 shares of AbCellera Biologics worth $466K as of Q2 2026.
  • Voleon Capital Management sold 63,151 AbCellera Biologics shares in Q2 2026, an estimated $309K.
  • AbCellera Biologics made up 0.01% of Voleon Capital Management's portfolio in Q2 2026, its #600 holding.
  • Voleon Capital Management first reported a position in AbCellera Biologics in Q3 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's AbCellera Biologics position peaked at $907K in Q4 2025.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.